Furthermore, TP53 mutation occurs in approximately 40–50% of sporadic CRC [45], with the mutation status being closely related to progression and outcome; patients with MUT TP53 appear more chemo-resistance and have poorer prognosis than those with WT TP53 [46]. This evidence concerns the gene TP53 and colorectal carcinoma.